Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study

Veronica Villani, Alessandro Ciuffoli, Luca Prosperini, Giuliano Sette

Research output: Contribution to journalArticlepeer-review


Background.- Zonisamide, a sulfonamide analog, is an antiepileptic drug with mechanisms of action similar to topiramate. Because of its pharmacodynamic and pharmacokinetics profiles, zonisamide is also potentially suitable for migraine prevention. Methods.- Tolerability and effectiveness of zonisamide for migraine prophylaxis in patients with a good response to topiramate, but interrupting it for intolerable side effects, were evaluated in 34 patients. After a 1-month period of wash-out, patients were treated with zonisamide (up to a 100 mg/day dosage) for 6 consecutive months. Results.- Zonisamide was well tolerated, only 4 (12%) patients reported transient and tolerable side effects. Mean number of days with headache per month was reduced from 14.9 ± 5.3 during the wash-out period to 2.5 ± 0.6 after 6 months of zonisamide (P

Original languageEnglish
Pages (from-to)287-291
Number of pages5
Issue number2
Publication statusPublished - Feb 2011


  • disability
  • migraine
  • topiramate
  • zonisamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study'. Together they form a unique fingerprint.

Cite this